Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research Report), BioLife Solutions (BLFS – Research Report) and RxSight (RXST – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Phathom Pharmaceuticals (PHAT)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals. The company’s shares closed last Thursday at $13.38.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
Currently, the analyst consensus on Phathom Pharmaceuticals is a Strong Buy with an average price target of $25.83.
See the top stocks recommended by analysts >>
BioLife Solutions (BLFS)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions today. The company’s shares closed last Thursday at $22.28.
According to TipRanks.com, Hewitt has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $33.25 average price target, which is a 47.1% upside from current levels. In a report issued on February 12, Lake Street also maintained a Buy rating on the stock with a $33.00 price target.
RxSight (RXST)
Bank of America Securities analyst Travis Steed maintained a Sell rating on RxSight today. The company’s shares closed last Thursday at $7.70.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for RxSight with a $10.50 average price target.
